Description
A nationwide Japanese study found no significant difference in in-hospital mortality between nursing home patients with sepsis treated empirically with piperacillin-tazobactam and those treated with carbapenems. Analyzing data from 8,025 patients admitted between 2018 and 2021, researchers reported mortality rates of 31.6% for piperacillin-tazobactam and 32.8% for carbapenems, with a risk difference of 1.2%. The findings suggest that both antibiotics offer comparable efficacy as empirical treatments for sepsis among high-risk nursing home residents, underscoring the need for careful antibiotic selection to balance effectiveness and antimicrobial stewardship.